title: Immediate diode laser peripheral iridoplasty as treatment of acute attack of primary angle closure glaucoma: a preliminary study.
abstract: OBJECTIVE
  To study the efficacy and safety of diode laser peripheral iridoplasty as a first-line treatment of acute primary angle-closure glaucoma (PACG) without the use of systemic anti-glaucoma medications.
  
  
  METHODS
  Nine consecutive patients with acute PACG were recruited into the study. Each patient received topical pilocarpine (4%), timolol (0.5%), apraclonidine (1%), and immediate diode laser peripheral iridoplasty as primary treatment. The intraocular pressures (IOPs) 15, 30, and 60 minutes after diode laser peripheral iridoplasty were documented by Goldmann applanation tonometry.
  
  
  RESULTS
  The mean IOP of this group of patients was reduced from 66.3 +/- 9.7 mm Hg, before diode laser peripheral iridoplasty, to 36.6 +/- 16.4 mm Hg at 15 minutes, 26.3 +/- 12.6 mm Hg at 30 minutes, and 18.9 +/- 8.4 mm Hg at 60 minutes after diode laser peripheral iridoplasty. In seven of the nine patients, the corneal edema cleared up 1 hour after diode laser peripheral iridoplasty. In the remaining patient, the cornea cleared up 12 hours after diode laser peripheral iridoplasty. No significant complications were encountered.
  
  
  CONCLUSIONS
  Diode laser peripheral iridoplasty, together with topical antiglaucoma medications without adjunctive systemic carbonic anhydrase inhibitors and hyperosmotic agents, appeared to be effective and safe in controlling the IOP in acute PACG.
authors.affiliation: Department of Ophthalmology, United Christian Hospital, Kwun Tong, Kowloon, Hong Kong.
authors.forename: J S
authors.initials: JS
authors.lastname: Lai
authors.forename: C C
authors.initials: CC
authors.lastname: Tham
authors.forename: J K
authors.initials: JK
authors.lastname: Chua
authors.forename: D S
authors.initials: DS
authors.lastname: Lam
mesh_terms: D000208:Acute Disease; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D003000:Clonidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D015812:Glaucoma, Angle-Closure / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure; D007498:Iris / Q000601:surgery*; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D008916:Miotics / Q000627:therapeutic use; D010862:Pilocarpine / Q000627:therapeutic use; D013999:Timolol / Q000627:therapeutic use; D014065:Tonometry, Ocular; D016896:Treatment Outcome
chemical_list: D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D008916:Miotics; D010862:Pilocarpine; D013999:Timolol; C016986:apraclonidine; D003000:Clonidine